TNIP3 Antibody

Code CSB-PA197029
Size US$166
Order now
Image
  • Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue, Primary antibody: CSB-PA197029(TNIP3 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
TNIP3
Alternative Names
TNIP3 antibody; ABIN3 antibody; LIND antibody; TNFAIP3-interacting protein 3 antibody; A20-binding inhibitor of NF-kappa-B activation 3 antibody; ABIN-3 antibody; Listeria-induced gene protein antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse
Immunogen
Synthetic peptide of Human TNIP3
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,WB
Recommended Dilution
Application Recommended Dilution
ELISA 1:1000-1:2000
WB 1:200-1:1000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Binds to zinc finger protein TNFAIP3 and inhibits NF-kappa-B activation induced by tumor necrosis factor, Toll-like receptor 4 (TLR4), interleukin-1 and 12-O-tetradecanoylphorbol-13-acetate. Overexpression inhibits NF-kappa-B-dependent gene expression in response to lipopolysaccharide at a level downstream of TRAF6 and upstream of IKBKB. NF-kappa-B inhibition is independent of TNFAIP3 binding.
Gene References into Functions
  1. TNIP3 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
  2. recombinant transgene facilitates the transcription of pro-inflammatory cytokines in fibroblast-like synoviocytes in rheumatoid arthritis PMID: 22093807
  3. ABIN-3 is a novel negative feedback regulator of LPS-induced NF-kappaB activation PMID: 17088249
  4. ABIN-3 is, thus, an IL-10-induced gene product capable of attenuating NF-kappaB in human macrophages yet is inoperative in mice and represents a basis for species-specific differences in IL-10 actions. PMID: 17485448
  5. Enhanced expression of ABIN-3 in monocytes is associated with sepsis PMID: 18081698
  6. This review defines ABIN-3 based on three different parameters: ability to bind A20; ability to inhibit NF-kappaB activation upon overexpression; the presence of specific short amino acid regions of strong homology, designated ABIN homology domains. PMID: 19464428
  7. adiponectin augmented the expression of A20, suppressor of cytokine signaling (SOCS) 3, B-cell CLL/lymphoma (BCL) 3, TNF receptor-associated factor (TRAF) 1, and TNFAIP3-interacting protein (TNIP) 3. PMID: 19617629

Show More

Hide All

Tissue Specificity
Highly expressed in lung, lymph node, thymus and fetal liver. Expressed at lower levels in bone marrow, brain, kidney, spleen, leukocytes and tonsils. Could be detected in heart, salivary gland, adrenal gland, pancreas, ovary and fetal brain. High levels
Database Links

HGNC: 19315

OMIM: 608019

KEGG: hsa:79931

STRING: 9606.ENSP00000057513

UniGene: Hs.208206

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*